REGENXBIO (RGNX) Projected to Post Earnings on Thursday

REGENXBIO (NASDAQ:RGNX) will likely be posting its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect REGENXBIO to post earnings of ($0.99) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:00 AM ET.

REGENXBIO Price Performance

Shares of RGNX stock opened at $9.14 on Thursday. The company has a market cap of $462.67 million, a price-to-earnings ratio of -2.63 and a beta of 1.08. REGENXBIO has a 1 year low of $5.03 and a 1 year high of $16.19. The firm has a fifty day moving average price of $11.70 and a 200-day moving average price of $11.41.

Analyst Ratings Changes

RGNX has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. Leerink Partners raised their price objective on REGENXBIO from $16.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Chardan Capital cut their price objective on REGENXBIO from $52.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. The Goldman Sachs Group reduced their target price on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Finally, Barclays assumed coverage on shares of REGENXBIO in a research note on Tuesday, January 27th. They set an “overweight” rating and a $37.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.80.

Hedge Funds Weigh In On REGENXBIO

Several hedge funds have recently modified their holdings of RGNX. Invesco Ltd. grew its position in REGENXBIO by 5.4% in the fourth quarter. Invesco Ltd. now owns 157,903 shares of the biotechnology company’s stock worth $2,274,000 after acquiring an additional 8,023 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in shares of REGENXBIO by 21.2% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 24,140 shares of the biotechnology company’s stock valued at $348,000 after purchasing an additional 4,224 shares during the last quarter. Vestal Point Capital LP purchased a new position in shares of REGENXBIO in the 4th quarter worth approximately $490,000. Virtus Investment Advisers LLC boosted its holdings in shares of REGENXBIO by 71.9% in the 4th quarter. Virtus Investment Advisers LLC now owns 19,181 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 8,026 shares during the period. Finally, Tudor Investment Corp ET AL bought a new position in shares of REGENXBIO during the 4th quarter valued at approximately $350,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.